The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

The Phase 3 study consisted of 2,400 participants in Asia, Africa, South America and the US. Xocova is also known as ensitrelvir, according to a statement. A once-daily pill, Xocova was approved ...

Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the ...

Shionogi previously agreed to sell a million doses of the drug, a protease inhibitor known as ensitrelvir and commercially as Xocova, to the government pending approval. The added supply agreement ...